Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 23, 100164
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 53 references indexed in Scilit:
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancerBJU International, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Bispecific T‐cell engagers for cancer immunotherapyImmunology & Cell Biology, 2014
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancerCancer, 2010
- ISOLATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGENJournal of Urology, 1998